MicroOptx
MicroOptx is an early-stage, privately held medical device company founded in 2014 in Maple Grove, Minnesota that leverages academic bioengineering to develop micro-scale optical technology, most likely for ophthalmic applications, and is staffed for clinical-stage development.
- Company typePrivate
- Founded2014
- HeadquartersMaple Grove, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MicroOptx does
MicroOptx is a privately held, early-stage medical device company founded in 2014 and headquartered in Maple Grove, Minnesota. The company positions itself as a translator of academic bioengineering research into medical device products, and its naming convention (the "Micro" prefix combined with "optx") implies work on micro-scale optical or implant technology, most likely targeted at ophthalmic indications. Operating with 11-50 employees, the company's disclosed leadership consists of a Chief Scientific Officer and co-founder (Roy Martin) and a VP of Clinical Affairs (Amy Derosier), an organizational shape consistent with a clinical-stage posture rather than commercial sales. The public web presence is minimal: the corporate website currently serves only an Apache-style directory listing (cgi-bin, Google site verification files, an "our-team/" subdirectory, and a sitemap) with no substantive product, pipeline, indication, or company narrative content, which either reflects very limited commercial activity or a deliberate low public profile.
The company has no disclosed products, no pricing model, no distribution channels, no named customers, no customer segmentation, and no revenue mechanics in the available data. No certifications, regulatory milestones (e.g., FDA 510(k) clearance or PMA approval), patents, trademarks, partnerships, or M&A activity are referenced. Marketing and distribution channels are explicitly noted as unavailable in the input, reinforcing the reading that MicroOptx is operating in a pre-commercial development phase rather than a go-to-market phase.
Capital-wise, MicroOptx has raised approximately $19.2 million across three disclosed funding events between 2015 and 2019, including a $2.4 million round in June 2015, a $13.8 million round in June 2019, and a $3 million round in August 2019 with HBM Healthcare Investments disclosed as an investor. The most recent capital event dates to mid-2019, and no post-2019 financing, operational milestones, or leadership additions appear in any source block. As a result, current operating momentum, pipeline progression, and commercial readiness cannot be confirmed from the available evidence.
MicroOptx firmographics
Firmographics- Name
- MicroOptx
- Website
- https://microoptx.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MicroOptx is an early-stage, privately held medical device company founded in 2014 in Maple Grove, Minnesota that leverages academic bioengineering to develop micro-scale optical technology, most likely for ophthalmic applications, and is staffed for clinical-stage development.
- Ownership category
- akta.pro rank
MicroOptx industry classification
Industry- Product category
- Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)
- akta.pro secondary industry
- Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)
Keywords
Where MicroOptx is headquartered
LocationHeadquarters
- HQ city
- Maple Grove
- HQ country
- United States
- HQ region
- North America
Markets served
MicroOptx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
MicroOptx product offering
Product offeringCore offering
MicroOptx is an early-stage medical device company that leverages academic bioengineering to develop its products. Specific product features, clinical indications, and target applications are not described in the available source data. The company operates with a small team (11–50 employees) and is privately held and venture funded.
Differentiator
Problem solved
Functional benefit
Companies that use MicroOptx
Customer profileIdeal customer profiles1 record
MicroOptx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MicroOptx partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
MicroOptx competitors and assessment
Company assessmentDirect peers
- Glaukos Corporation: Glaukos is the pioneer and market leader in micro-invasive glaucoma surgery (MIGS) with its iStent platform. It is the most directly comparable commercial-stage peer for a company developing micro-optical or micro-scale glaucoma implants targeting the same ophthalmic surgeons and indications.
- Sight Sciences: Sight Sciences markets the OMNI Surgical System and Trabeculo360 for micro-invasive glaucoma and canaloplasty procedures. As a growth-stage MIGS company with a direct overlap in target indication, customer (glaucoma surgeons), and minimally-invasive approach, it is a strong direct comparable.
- iStar Medical: iStar Medical is developing the MINIject suprachoroidal MIGS implant, a micro-scale glaucoma drainage device. Its minimally-invasive, implant-based approach targeting IOP reduction makes it a strong direct comparable to a micro-optical or micro-implant glaucoma device.
- New World Medical (Belkin Vision): Belkin Vision (operating alongside New World Medical) develops laser-based MIGS solutions (e.g., Eagle directSelective laser trabeculoplasty) for glaucoma. It competes for the same surgeon customers and same glaucoma treatment paradigm as a micro-scale implant approach.
Emerging players
- Ocular Therapeutix: Ocular Therapeutix is a clinical-to-commercial-stage ophthalmic company developing sustained-release drug delivery and device-based therapies for glaucoma and other eye diseases. Its emerging status and overlap in glaucoma innovation make it a relevant emerging-player comparable for a small, micro-scale device company.
Broad incumbents
- Bausch + Lomb: Bausch + Lomb is a diversified ophthalmic medical device and pharmaceutical company with significant presence in glaucoma and surgical devices. Its broad portfolio and surgeon relationships position it as a benchmark incumbent and potential strategic acquirer for micro-scale glaucoma technologies.
- Santen Pharmaceutical: Santen is a Japan-based global ophthalmic specialty company with a strong glaucoma franchise (and historical interest in InnFocus Microshunt). As a strategic acquirer and incumbent glaucoma player, it represents a relevant comparable and potential exit partner for a micro-optical glaucoma implant.
- Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic diagnostic and surgical devices, including optical coherence tomography and surgical microscopes. Its deep optical engineering heritage and surgical footprint make it a relevant broad incumbent for a micro-optical implant company.
- Alcon: Alcon is the largest dedicated ophthalmic medical device company globally, with a broad surgical and vision-care portfolio including the Hydrus Microstent (acquired via Ivantis). It sets the commercial benchmark and competitive ceiling for any micro-scale glaucoma implant.
- Johnson & Johnson Vision: J&J Vision is a major ophthalmic surgery franchise with products across cataract, refractive, and glaucoma. Its scale, global distribution, and history of acquiring MIGS-adjacent technologies (e.g., SightLine) make it a relevant broad incumbent peer and potential acquirer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
MicroOptx social profiles
Digital presenceMicroOptx financial estimates
Financial estimateRevenue estimate
Valuation estimate
MicroOptx leadership team
Management profileNumber of profiles
Profiles2 records
MicroOptx funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MicroOptx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MicroOptx
What does MicroOptx do?
MicroOptx is an early-stage medical device company that leverages academic bioengineering to develop its products. Specific product features, clinical indications, and target applications are not described in the available source data. The company operates with a small team (11–50 employees) and is privately held and venture funded.
When was MicroOptx founded?
MicroOptx was founded in 2014. It employs 11 to 50 people.
Where is MicroOptx based?
MicroOptx is headquartered in Maple Grove, United States, in the North America region.
Who are MicroOptx's main competitors?
Direct peers on record are Glaukos Corporation, Sight Sciences, iStar Medical and New World Medical (Belkin Vision). Ocular Therapeutix is listed as an emerging player. Broad incumbents are Bausch + Lomb, Santen Pharmaceutical, Carl Zeiss Meditec, Alcon and Johnson & Johnson Vision.
Does MicroOptx have an API?
No public API is recorded for MicroOptx.
What industry is MicroOptx in?
MicroOptx's product category is Medical Devices. Its primary akta.pro industry code is HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling), with a secondary code of HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal). Its NAICS code is 334510 and its SIC code is 3841.